Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study

BACKGROUND: The relative efficacy of lapatinib vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC) patients, who progressed on first-line trastuzumab, is still unclear. The objective of this population based cohort study was to compare outcomes of lapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammerman, Ariel, Greenberg-Dotan, Sari, Feldhamer, Ilan, Bitterman, Haim, Yerushalmi, Rinat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574060/
https://www.ncbi.nlm.nih.gov/pubmed/26375590
http://dx.doi.org/10.1371/journal.pone.0138229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574060/
https://www.ncbi.nlm.nih.gov/pubmed/26375590
http://dx.doi.org/10.1371/journal.pone.0138229

Ejemplares similares